DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

DBV Technologies announced that CEO Daniel Tassé will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18 at 8:40 am ET. This event will be hosted in a virtual format, allowing interested parties to access the webcast through the Investors & Media section of the Company’s website. A replay will be available after the event.

DBV Technologies, based in Montrouge, France, focuses on developing Viaskin™, a proprietary technology for food allergy treatment. The Company's shares trade under the ticker DBVT on Nasdaq.

Montrouge, France, February 14, 2022

DBV Technologies to Present at the 11th Annual SVB Leerink Global Healthcare Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18^th at 8:40 am ET.

A webcast of the presentation will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/

A replay of the presentation will also be available on DBV Technologies’ website after the event.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com

Attachment

• PDF Version

FAQ

When is DBV Technologies presenting at the SVB Leerink Global Healthcare Conference?

DBV Technologies will present on February 18, 2022, at 8:40 am ET.

Who is presenting for DBV Technologies at the conference?

Daniel Tassé, the Chief Executive Officer of DBV Technologies, will be presenting.

Where can I find the webcast for DBV Technologies' presentation?

The webcast will be available on the Investors & Media section of DBV Technologies' website.

What is the focus of DBV Technologies' presentation at the conference?

The presentation will likely focus on DBV's technology platform, Viaskin™, and its applications in immunotherapy.

What ticker symbol represents DBV Technologies on Nasdaq?

DBV Technologies trades under the ticker symbol DBVT on the Nasdaq.